32nd International

Precision Med TRI-CON

March 11-13, 2025 | Town and Country Resort San Diego, CA

Over 30 Years of Connecting the Precision Medicine Community

2025 Conference Programs

March 11-12

- AI in Precision Medicine
- Implementing Precision Medicine
- At-Home & Point-of-Care Diagnostics
- Liquid Biopsy
- Spatial Biology and Single-Cell Multiomics

March 12-13

- Diagnostics Market Access
- Precision Medicine Beyond Oncology
- Infectious Disease Diagnostics
- Multi-Cancer Early Detection
- Clinical Biomarkers & Companion Dx

Final Weeks to Register

Featured Speakers

Peter Foley
CEO
LetsGetChecked

Mara Aspinall
Partner
Illumina Ventures

Gabriele Allegri
VP, Global Commercial Precision Medicine
Johnson & Johnson

Lisa Alderson
CEO
Adela

Alex Aravanis
CEO
Moonwalk Biosciences

Jenny Rooke
Managing Director
Genoa Ventures

Omar Perez
Head of Medical Diagnostics
AstraZeneca

Susan Tousi
CEO
DELFI Diagnostics

TABLE OF CONTENTS

#TRICON | **TriConference.com**

Organized by Cambridge Healthtech Institute

Premier Sponsors: DISCOVERY LIFE SCIENCES · Roche

32nd International

Precision Med TRI-CON

March 11-13, 2025 | Town and Country Resort San Diego, CA

Table-of-Contents

Conference Programs

March 11-12

- AI in Precision Medicine
- Implementing Precision Medicine
- At-Home & Point-of-Care Diagnostics
- Liquid Biopsy
- Spatial Biology and Single-Cell Multiomics

March 12-13

- Diagnostics Market Access
- Precision Medicine Beyond Oncology
- Infectious Disease Diagnostics
- Multi-Cancer Early Detection
- Clinical Biomarkers & Companion Dx

> TRI-CON is one of the most important events for us to attend and be seen at. It brings together a fantastic combination of potential clients and collaborators in one great location.
>
> *Head of Product Development, MiniFAB*

Over 30 Years of Connecting the Precision Medicine Community

For 3 decades, the Precision Med TRI-CON has served as the leading international meeting place for the diagnostics and precision medicine community. Join over a thousand international thought leaders to discuss the latest research, technologies, innovation, and business models in implementing precision medicine, biomarkers, and companion diagnostics, genomic medicine, and artificial intelligence; innovation, and market access strategies for at-home diagnostics, point-of-care testing and molecular diagnostics for infectious diseases; liquid biopsy and advanced diagnostics for precision oncology, including multi-cancer early detection and minimal residual disease testing. Emerging implications of faster and cheaper sequencing, AI and digital tools, and spatial biology and single-cell multiomics in advancing precision medicine will be covered in 2025. The new track on precision medicine beyond oncology will cover applications in immunology, neurology, and metabolic diseases. Join us in sunny San Diego for the in-person networking and visionary and thought-provoking keynote discussions you've come to expect from the TRI-CON!

2024

Attendee Demographics

58% Biotech/Commercial
15% Healthcare
14% Academic
7% Pharma
2% CRO
2% Societies
2% Other



45% Executive
26% Scientist
19% Sales & Marketing
9% Manager
1% Other

Sponsorship & Exhibit Opportunities

Exhibitors will have an opportunity to enjoy in-person and virtual facilitated networking opportunities with qualified delegates, making it the perfect platform to launch a new product, collect feedback, and generate new leads from around the world.

How Sponsoring/Exhibiting Promotes & Benefits Your Business:

- Generate qualified leads consisting of actual decision-makers from within your focus area
- Network with senior-level professionals and generate leads during dedicated exhibit hall hours, lunches, etc.
- Promote your company's participation in the Event Materials—including contact information and 50-word description
- Increase your brand awareness and drive traffic to your website through our various marketing campaigns
- Increase dedicated networking time in the exhibit hall

Podium Presentations

Available within Main Agenda!

Showcase your solutions to a guaranteed, targeted audience through a 15- or 30-minute presentation during a specific conference program, breakfast, or lunch. Package includes exhibit space, onsite branding, and access to cooperative marketing efforts by CHI. For the luncheon option, lunches are delivered to attendees already seated in the main session room. Presentations do sell out early.

One-on-One Meetings

Work with us to identify your target prospects and we will schedule meetings for you. Think of us as your inside sales team with all your hottest leads in close reach. Opportunities sold on a very limited basis.

Invitation-Only Dinner/Hospitality Suite

Sponsors will select their top prospects from the conference preregistration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations, conduct follow-up, and confirm attendees. The evening will be customized to meet with your specific objectives.

Exhibit Hall Networking Reception Sponsorship

Your company will be recognized as the exclusive sponsor of the Welcome Reception on day 1 to be held in the Exhibit Hall. Use this lively social occasion to launch a new product or solution and drive delegates to your exhibit booth.

Additional sponsorship & branding opportunities include:

- Meter Boards
- Lanyards—**SOLD!**
- Foot Trails—NEW
- Keynote Chair Drop
- Tote Bag Exclusive Sponsorship
- Water Bottles
- Conference Track Notebooks
- Tote Bag Insert
- Chair Drop in Session Room

How will CHI ensure that delegates visit the exhibit hall?

- Welcome receptions
- Themed functions
- Refreshment breaks
- Exhibit Hall Booth Crawl
- Raffles and more

For additional information, please contact:

Companies A-K
Phillip Zakim-Yacouby
Sr. Manager, Business Development
781-247-1815
philzy@cambridgeinnovationinstitute.com

Companies L-Z
Katelin Fitzgerald
Sr. Manager, Business Development
781-247-1824
kfitzgerald@healthtech.com

Thank You to Our Sponsors

Premier Sponsors:

DISCOVERY LIFE SCIENCES

Roche

Corporate Sponsors:

altratech

biodesix

BIOIVT ELEVATING SCIENCE

CASTLE BIOSCIENCES

DCN DX

MilliporeSigma

Corporate Support Sponsor:

axxin INNOVATION TO IMPACT

> The Tri-Conference captured the key topics of the moment combined with a very diverse set of attendees.
>
> *CCO, OmniSeq*

Plenary Keynote Program

TUESDAY, MARCH 11

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction *(Sponsorship Available)*

8:15 Plenary Keynote Fireside Chat: Talk Title to be Announced
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine
Interviewed by:
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine

Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences

Peter Foley, Founder & CEO, LetsGetChecked
Interviewed by:
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: Driving Innovation in Precision Medicine: CEO Perspective

Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Susan Tousi, CEO, DELFI Diagnostics

WEDNESDAY, MARCH 12

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 Plenary Keynote Introduction *(Sponsorship Available)*

8:15 PANEL DISCUSSION: Investing in Precision Medicine Innovation: What Defines Success?



Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Ajit Singh, PhD, Partner, Artiman Ventures
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:15 PANEL DISCUSSION: Tech Trends in Precision Medicine

Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine

Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.
Panelists:
Aaron Sin, Senior Director Research & Technology Development, MilliporeSigma
Damon Hostin, Lead, Health System Market Access, Illumina, Inc.
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics
Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

TABLE OF CONTENTS

2025 Featured Speakers

Precision Med TRI-CON

Mara Aspinall
Partner
Illumina Ventures

Peter Foley
CEO
LetsGetChecked

Lisa Alderson
CEO
Adela

Gabriele Allegri
VP, Global Commercial Precision Medicine
Johnson & Johnson

Alex Aravanis
CEO
Moonwalk Biosciences

Omar Perez
Head of Medical Diagnostics
AstraZeneca

Jenny Rooke
Managing Director
Genoa Ventures

Ajit Singh
Partner
Artiman Ventures

Susan Tousi
CEO
DELFI Diagnostics

Steffan Ho
VP, Translational Oncology
Pfizer

Lourdes Barrera
Executive Director, Precision Medicine
Merck

Christopher Conn
Director, Diagnostics Strategy
Amgen

Andrea L. Stevens
Senior Director
Precision Medicine Access, Johnson & Johnson

Ezra Cohen
CMO, Oncology
Tempus Labs

Hoi-Ying Elsie Yu
Laboratory Director, Point-of-Care Testing
Geisinger Health

Michael Hodsdon
VP, Clinical Diagnostics Laboratory
Eli Lilly

Wendy Rubinstein
Senior Scientific Officer, Cancer Prevention
NCI

Jai Pandey
Head, Global Device Regulatory IVD/CDx
Sanofi

Edward Abrahams
Former President
Personalized Medicine Coalition

Christopher Hartshorn
Chief, Digital & Mobile Technologies
NCATS

Robert A. Smith
SVP, Center for Cancer Screening
American Cancer Society

Kyle Farh
VP, Artificial Intelligence Lab
Illumina

Howard Scher
Head, Biomarker Development Program
Memorial Sloan Kettering Cancer Center

Shawn Carlson
Vice President, Head of Market Access
Roche Diagnostics

Sudhir Srivastava
Chief, Cancer Biomarkers Research
NCI

TUESDAY, MARCH 11

7:00 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 Plenary Keynote Fireside Chat: A New Era in Healthcare: Making Precision Medicine a Reality
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Plenary Keynote Fireside Chat: Talk Title to be Announced
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine





Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Personalized or precision medicine depends upon linking prescribed therapies to diagnostics so that the right patient gets the right drug at the right time. Yet bringing the therapeutics and diagnostics together does not come easily as the pharmaceutical and diagnostic industries do not share the same business models or cultures. This panel discussion will explore what pharmaceutical executives look for when partnering with colleagues in diagnostics to develop targeted therapies.
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

9:30 Grand Opening Refreshment Break in the Exhibit Hall with Poster Viewing

CLINICAL IMPLEMENTATION OF AI IN PRECISION MEDICINE

10:15 Chairperson's Remarks
Chris M. Hartshorn, PhD, Chief, Digital & Mobile Technologies Section—CTSA Program, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

10:20 From Discovery to Commercialization: Best Practices to Harness AI's Potential to Enhance Patient Outcomes
Vikram Chaudhery, PhD, Partner, Genoa Ventures
With the explosion of advanced digital innovations now employed across all aspects of healthcare, the journey of a data point is no longer linear. What does its new journey look like? What is the feedback loop from patients and clinicians to early development scientists and vice versa? How can companies ensure strategic and thoughtful investments in these data-first approaches? Most importantly, what do any of these ultimately do for patients?

10:50 Moving AI towards Healthcare by Way of Impactful Translational Science and the NIH
Chris M. Hartshorn, PhD, Chief, Digital & Mobile Technologies Section—CTSA Program, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)
AI, in all of its forms, boils down to looking at and learning from data, better—its potential impact to medicine and healthcare is well known—yet its impact remains tethered by our ability to leverage these tools without introducing more bias in the algorithms generated. This talk will discuss translational science efforts and workforce training, funded by the NIH, to focus on Good Algorithmic Practice and its propagation.

11:20 Integration of AI and Biomarkers in New Evolutionary Clinical Trial Designs
Andrea Bild, PhD, Program Manager, Advanced Research Projects Agency for Health (ARPA-H)
Despite advances in tumor measurement technologies and computational approaches such as AI for biomarker discovery, there remains a critical gap in adapting treatments to the dynamic biology of tumors as they mutate and develop resistance to therapies. This presentation will discuss a new national program, "ADAPT: ADvanced Analysis for Precision cancer Therapy" that will support the identification of multi-gene biomarkers from multi-modal data to inform therapy choices.

11:50 Sponsored Presentation *(Opportunity Available)*

12:20 pm Session Break

12:25 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

12:55 Session Break

CLINICAL IMPLEMENTATION OF AI IN PRECISION MEDICINE (CONT.)

1:20 Chairperson's Remarks
Chris M. Hartshorn, PhD, Chief, Digital & Mobile Technologies Section—CTSA Program, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)

1:25 FDA Regulations of Artificial Intelligence in Precision Medicine
Wenjing Wang, Associate Director, Global Regulatory Affairs & Clinical Safety, Merck & Co., Inc.
The FDA regulates artificial intelligence in precision medicine by ensuring that AI-based medical devices and software meet rigorous safety, efficacy, and quality standards before they are approved for clinical use. This presentation will cover some FDA frameworks for continuous oversight and post-market surveillance to address the unique challenges presented by adaptive learning algorithms.

1:55 PANEL DISCUSSION: AI-Driven Precision Medicine: Harnessing Biomarkers, Data, and Drug Discovery to Advance Oncology

Moderator: Arturo Loaiza-Bonilla, MD, Co-Founder & CMO, Massive Bio, Inc.

This session explores AI-driven precision medicine in oncology, featuring experts from Massive Bio, AbbVie, and Foundation Medicine. Discussions will focus on the impact of AI and biomarkers in advancing cancer treatments and optimizing clinical trials.

Panelists:

Selin Kurnaz, PhD, Co-Founder and CEO, Massive Bio, Inc.

Archana Simmons, PhD, Senior Scientific Director, Head of CDx and Biomarkers, Medical Affairs and Health Impact, AbbVie

Heather Jorajuria, Senior Vice President, Clinical Trial & Scientific Operations, Foundation Medicine

Hisani Madison, PhD, MPH, Vice President, Precision Medicine & Medical Device Development, PathAI

2:25 Presentation to be Announced

2:55 Refreshment Break in the Exhibit Hall with Poster Viewing *(Sponsorship Opportunity Available)*

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 Chairperson's Remarks

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences

Peter Foley, CEO and Founder, LetsGetChecked

In this fireside chat, Peter Foley, CEO and founder of LetsGetChecked, will explore the mission and vision that have driven the company's rapid growth and innovation in home health management. He will share insights into the journey of scaling from a direct-to-consumer model to a robust business-to-business platform, addressing the challenges of integrating health insights and advanced clinical diagnostics with exceptional customer care.

Plenary Keynote Fireside Chat: Talk Title to be Announced

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: Driving Innovation in Precision Medicine: CEO Perspective




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

Panelists:

Lisa Alderson, CEO, Adela, Inc.

Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences

Susan Tousi, CEO, DELFI Diagnostics

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

WEDNESDAY, MARCH 12

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 Chairperson's Remarks

Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 PANEL DISCUSSION: Investing in Precision Medicine Innovation: What Defines Success?




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

Panelists:

Ajit Singh, PhD, Partner, Artiman Ventures

Jenny Rooke, PhD, Managing Director, Genoa Ventures

Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

9:00 Transition to Sessions

AI ADOPTION TO ACCELERATE PERSONALIZED MEDICINE

9:05 Chairperson's Remarks

9:10 Leveraging AI to Accelerate Research, Inform Clinical Management, and Make Life Better

Ezra Cohen, MD, CMO, Oncology, Tempus Labs, Inc.

The ability of AI to integrate and interrogate multi-modal, large datasets and inputs within seconds has ushered in a new era in medicine that is changing every area of practice. Oncology lends itself well to AI applications because it is a genomically driven disease with complex management pathways. This presentation will discuss platforms that optimize treatment selection, drug discovery, and patient empowerment.

9:40 PANEL DISCUSSION: Policy Considerations for Facilitating Broad Implementation and Uptake of AI in Personalized Medicine

Moderator: Cynthia A. Bens, Senior Vice President, Public Policy, Personalized Medicine Coalition

There are many use cases for Artificial Intelligence (AI) in health care relevant to personalized medicine. Depending on the use case, developers may be subject to different regulatory requirements and the pathways to coverage and reimbursement may be unclear. Panelists in this session will discuss current challenges for AI innovation and policy considerations that can help realize AI's potential for improving patient access to personalized medicine.

Panelists:

Mark Stewart, PhD, Vice President, Science Policy, Friends of Cancer Research

Ilan Wapinski, PhD, Head, Biomarkers & Patient Stratification, Precision Medicine & Computational Biology Group, Sanofi

10:10 Sponsored Presentation *(Opportunity Available)*

10:40 Coffee Break in the Exhibit Hall with Poster Viewing

OMICS, DATA, AND AI IN PRECISION MEDICINE

11:25 Chairperson's Remarks

11:30 Deep Learning and Genomics for Drug Target Discovery
Kyle Farh, MD, PhD, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina
We apply the latest deep learning technologies to improve interpretation of human genetic variation in large biobank-scale cohorts, comprising hundreds of thousands of individuals with medical record data, and demonstrate novel insights for genetic risk prediction and drug target discovery.

12:00 pm PANEL DISCUSSION: Omics, Data, and AI in Precision Medicine
Moderator: Fay Lin, PhD, Senior Editor, Genetic Engineering & Biotechnology News
The promise of AI for understanding disease biology, drug discovery, and diagnostics hinges on the rise of large omics datasets. In this panel, experts from Tempus AI, Illumina, and PrecisionLife will explore the key considerations for omics data generation and curation. They'll also discuss crucial data challenges, such as accessibility and representation, that might prevent AI from reaching its full potential in precision medicine.
Panelists:
Ryan J. Taft, PhD, Senior Vice President, Genomics R&D, Tempus AI
Kyle Farh, MD, PhD, Vice President & Distinguished Scientist, Artificial Intelligence Lab, Illumina
Steve Gardner, PhD, CEO and Co-Founder, PrecisionLife
Eleanor A. Howe, PhD, Founder & CEO, Diamond Age Data Science

1:00 Lunch in the Exhibit Hall

2:00 Close of Artificial Intelligence in Precision Medicine Conference

> "The one conference for state-of-the-art presentations on disease mechanisms and drug development and therapeutics."
>
> *Chief Science Officer, AMCP BBCIC, LLC*

TUESDAY, MARCH 11

7:00 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 Plenary Keynote Fireside Chat: A New Era in Healthcare: Making Precision Medicine a Reality
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Plenary Keynote Fireside Chat: Talk Title to be Announced
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine





Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Personalized or precision medicine depends upon linking prescribed therapies to diagnostics so that the right patient gets the right drug at the right time. Yet bringing the therapeutics and diagnostics together does not come easily as the pharmaceutical and diagnostic industries do not share the same business models or cultures. This panel discussion will explore what pharmaceutical executives look for when partnering with colleagues in diagnostics to develop targeted therapies.
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

9:30 Grand Opening Refreshment Break in the Exhibit Hall with Poster Viewing

IMPLEMENTING PRECISION MEDICINE AND COMPANION DIAGNOSTICS

10:15 Chairperson's Remarks

10:20 Challenges & Opportunities for Employing Innovative Technologies in Companion Diagnostic Development
Christopher Conn, PhD, Director, Global Diagnostic Strategy, Precision Medicine, Amgen
This talk will summarize the current state of approved companion diagnostics from a technology perspective, and provide critical insights into emerging diagnostic technologies. It will highlight some emerging technologies such as AI-assisted digital pathology, focusing on how these technologies help address limitations of standard approaches, balanced with challenges and barriers that limit the adoption of such technologies.

10:50 Clinical Development Enabled by Precision Medicine: The Amivantamab CDx Story (So Far)
Fernando Cruz-Guilloty, PhD, Director, Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine
Amivantamab (Ami) is a bispecific antibody against EGFR and MET that has been developed to address unmet needs in non-small cell lung cancer (NSCLC). The efficacy of Ami has been demonstrated in pivotal studies for NSCLC with EGFR Exon 20 insertion mutations and NSCLC with common EGFR mutations (Exon 19 deletion and L858R). This talk will describe precision medicine enabling clinical development success for Ami, highlighting various companion diagnostics (CDx).

11:20 Implementation Science: The Precision Medicine Perspective
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
As precision medicine evolves, the need for effective implementation strategies becomes paramount to translate research findings into clinical practice. In this talk, we will explore the integration of implementation science within precision medicine, focusing on frameworks, methodologies, and real-world applications. Key topics will include the assessment of barriers to adoption, strategies for stakeholder engagement, and the evaluation of outcomes.

11:50 Sponsored Presentation *(Opportunity Available)*

12:20 pm Session Break

12:25 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

12:55 Session Break

IMPLEMENTING PRECISION MEDICINE AND COMPANION DIAGNOSTICS (CONT.)

1:20 Chairperson's Remarks

1:25 PANEL DISCUSSION: Best Practices for Development and Global Utilization of Precision Medicines
Moderator: Hakan Sakul, PhD, Owner and President, Precision Dx Strategies, Inc.
While multiple cancer indications have been the primary beneficiaries of precision medicines, scientific and technological improvements are now enabling such medicines for non-cancer indications. This expert panel will focus on efforts to develop precision medicines, impact of technological advances on future medicines, advances in prevailing science across disease states, equitable access to precision medicine trials, current challenges in global regulatory and reimbursement environments, and ways to remove barriers to access.
Panelists:
Brian Caveney, MD, JD, MPH, CMO & CSO, President, Early Development Research Laboratories, Labcorp
Fernando Cruz-Guilloty, PhD, Director, Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine
Elaine Katrivanos, Vice President, Regulatory Affairs, Tempus

Jean-François Martini, PhD, MSc, Biomarker Clinical Assay and Technology Group Head, Translational Science Operations, Pfizer Oncology
Marielena Mata, PhD, Senior Director, Clinical Biomarkers, Vividion Therapeutics

2:25 Sponsored Presentation *(Opportunity Available)*

2:55 Refreshment Break in the Exhibit Hall with Poster Viewing
(Sponsorship Opportunity Available)

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences
Peter Foley, CEO and Founder, LetsGetChecked
In this fireside chat, Peter Foley, CEO and founder of LetsGetChecked, will explore the mission and vision that have driven the company's rapid growth and innovation in home health management. He will share insights into the journey of scaling from a direct-to-consumer model to a robust business-to-business platform, addressing the challenges of integrating health insights and advanced clinical diagnostics with exceptional customer care.

Plenary Keynote Fireside Chat: Talk Title to be Announced
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: Driving Innovation in Precision Medicine: CEO Perspective




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Susan Tousi, CEO, DELFI Diagnostics

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

WEDNESDAY, MARCH 12

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 PANEL DISCUSSION: Investing in Precision Medicine Innovation: What Defines Success?




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Ajit Singh, PhD, Partner, Artiman Ventures
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

9:00 Transition to Sessions

MARKET ACCESS FOR PRECISION MEDICINE AND MOLECULAR TESTING

9:05 Chairperson's Remarks

9:10 Precision Medicine Unlocked: Closing Testing Gaps to Transform Patient Care in the US
Archana Simmons, PhD, Senior Scientific Director, Head of CDx and Biomarkers, Medical Affairs and Health Impact, AbbVie

9:40 Case Study in Addressing Access Barriers: Clinical Implementation of Exome and Genome Sequencing in Pediatric Rare Disease
Stacey Brown, Market Access Lead, Optum Genomics
This session will review a case study involving implementation across several health care ecosystem stakeholders (payer, provider, industry) aimed at addressing various issues associated with the commercial clinical adoption of exome and genome sequencing in pediatric rare disease. It will underscore the complexity of improving access to genomic testing and the importance of a multifaceted approach.

10:10 Re-Envisioning Reimbursement to Support Technological Innovations that Improve Patient Care and Outcomes
Paul Gerrard, MD, Head, Global Market Access and Reimbursement, PathAI
Reimbursement systems traditionally are designed around conventional healthcare delivery workflows such as patient visits, laboratory testing, and follow-up care, which are codified into billable services. While early health technology, like EMRs primarily functioned in a supportive role, health technologies today increasingly enable doctors to do more. Reimbursement

models and processes aren't designed for many healthcare innovations, and they are slowly evolving in reaction to the emergence of these newer technologies.

10:40 Coffee Break in the Exhibit Hall with Poster Viewing

DIRECT ACCESS TESTING

11:25 Chairperson's Remarks
Joe Keenan, Head, Life Sciences, LetsGetChecked

11:30 Precision Medicine Reimbursement—A Landscape Overview
Matt Bacigalupi, Director, Medicare Account Management, Novartis
Precision Medicine has rapidly evolved over the last decade; as a part of the dynamic future of healthcare, where do we stand with payer coverage and reimbursement? What steps can we take to better understand how coverage decisions are going to be made and what steps can be taken "pre" and "post" market entrance to help support coverage?

12:00 pm PANEL DISCUSSION: Direct Access Testing—Greatest Challenges in Getting Patients the Results They Need
Moderator: Joe Keenan, Head, Life Sciences, LetsGetChecked
Direct access testing or 'consumer-initiated testing' has grown exponentially in the last 5 years. Much is attributable to the familiarization of home testing kits such as those used during the pandemic for Covid-19 antigen testing. Patients are moving to managing their health on their own terms and we as an industry need to appropriately facilitate. This panel will discuss test access/ affordability as well as regulatory topics and operational aspects.
Panelists:
Robert Mordkin, MD, CMO, LetsGetChecked
Lesley Northrop, PhD, Chief Diagnostic Officer, Everly Health
Matt Bacigalupi, Director, Medicare Account Management, Novartis
Amy Summy, Executive Vice President and Chief Marketing Officer, Labcorp
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics

1:00 Lunch in the Exhibit Hall

2:00 Close of Implementing Precision Medicine Conference

TUESDAY, MARCH 11

7:00 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 Plenary Keynote Fireside Chat: A New Era in Healthcare: Making Precision Medicine a Reality
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Plenary Keynote Fireside Chat: Talk Title to be Announced
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine





Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Personalized or precision medicine depends upon linking prescribed therapies to diagnostics so that the right patient gets the right drug at the right time. Yet bringing the therapeutics and diagnostics together does not come easily as the pharmaceutical and diagnostic industries do not share the same business models or cultures. This panel discussion will explore what pharmaceutical executives look for when partnering with colleagues in diagnostics to develop targeted therapies.
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

9:30 Grand Opening Refreshment Break in the Exhibit Hall with Poster Viewing

EXPANDING CLINICAL ADOPTION OF HOME TESTING

10:15 Chairperson's Remarks
Elsie Yu, PhD, Director, Clinical Pathology Informatics, System and Core Laboratory Director, Chemistry, Toxicology and Point-of-Care Testing, Geisinger Laboratory Medicine; Associate Professor, Geisinger Commonwealth School of Medicine

10:20 Direct-to-Consumer Testing—What Can Be Done to Improve Clinical Adoption?
Elsie Yu, PhD, Director, Clinical Pathology Informatics, System and Core Laboratory Director, Chemistry, Toxicology and Point-of-Care Testing, Geisinger Laboratory Medicine; Associate Professor, Geisinger Commonwealth School of Medicine
Direct-to-consumer (DTC) testing can take the form of at-home testing, at-home sample collection, or traditional phlebotomy/laboratory testing at a clinical laboratory. Post-COVID pandemic, we have experienced both a rise and a fall of DTC testing. Some companies have filed for bankruptcy, while others are thriving. This presentation will discuss long-term strategy that focuses on enhancing clinical utility and adoption.

10:50 Advancements from Biology to Chips to Digital Tools Plus a New Era of Medicine will Drive Point of Care Forward
Michael J. Mina, MD, PhD, CEO, Biohealth Engineering
POC technologies have been critical in streamlining medical care and public health efforts. A burgeoning infrastructure is rapidly advancing the state of POC devices. From synthetic biology, to robotics, to digital health, a new ecosystem is developing and with it advances that can alter the position of POC testing in our daily lives, in the clinic, and in the home. How to leverage these technologies appropriately will be the challenge.

11:20 Advancing POC Diagnostics for Acute Hospital-Level Care in the Home
Jared Conley, MD, PhD, MPH, Assistant Professor, Harvard Medical School; Associate Director, Healthcare Transformation Lab
The rapidly developing technologies of point-of-care diagnostics have great potential to unleash our capacity to deliver more and more care in the healing environment of patients' homes. This session will briefly review the current/emerging acute and advanced at-home care models and then explore point-of-care diagnostic opportunities that enable the monitoring and management of dynamic clinical risk and enable us to safely and effectively serve more patients at home.

11:50 Presentation to be Announced

12:05 pm Sponsored Presentation *(Opportunity Available)*

12:20 Session Break

12:25 LUNCHEON PRESENTATION: Case Studies in Lateral Flow: Pioneering Sensitivity and Versatility for Better Diagnostics
Elizabeth Heisler, Immunoassay Business Development Manager, Commercial, MilliporeSigma
In lateral flow diagnostics, improving assay performance is essential for better outcomes. Learn how optimizing sample handling and key raw materials can significantly improve signal quality and assay consistency. Through real-world case studies, we will demonstrate advancements in reliable and versatile at-home testing solutions. These innovations illustrate how improved sensitivity and stability make diagnostics more accessible and effective, for better healthcare outcomes for everyone.

12:55 Session Break

EXPANDING CLINICAL ADOPTION OF HOME TESTING (CONT.)

1:20 Chairperson's Remarks

Elsie Yu, PhD, Director, Clinical Pathology Informatics, System and Core Laboratory Director, Chemistry, Toxicology and Point-of-Care Testing, Geisinger Laboratory Medicine; Associate Professor, Geisinger Commonwealth School of Medicine

1:25 At-Home Testing vs. At-Home Specimen Collection
Elizabeth M. Marlowe, PhD, D(ABMM), Executive Scientific Director, Head, R&D Infectious Diseases & Immunology, Quest Diagnostics
Remote specimen collection with samples sent to a central laboratory as well as at-home testing options have shifted the paradigm in the patient journey. The goal of this talk is to explore what is needed to support the changing paradigm and reduce barriers for diagnostic testing.

1:55 Mobile and Home Health: What We Learned from COVID-19 and the Future of Point-of-Care Testing
Nam K. Tran, PhD, Professor, Pathology and Laboratory Medicine, University of California, Davis
The COVID-19 pandemic accelerated the expansion and acceptance of mobile and at-home testing. With advancements in molecular diagnostics, home-based testing has become more feasible, while the integration of smart devices and artificial intelligence is set to further transform the landscape. This presentation offers an overview of the mobile and at-home testing solutions that emerged during the pandemic and explores future directions, potential opportunities, and challenges in this evolving field.

2:25 Optimizing Molecular Diagnostic Assay Development for RNA Targets: Enhancing Performance and Reducing Costs
Alex Latta, PhD, Field Application Consultant, Roche CustomBiotech
Molecular diagnostic developers face both internal and external pressures to reduce costs and improve assay performance. For example, the reverse transcription step in an RT-PCR assay drastically increases complexity encountered in molecular diagnostics. Using fast, inhibitor tolerant, and lyo-compatible reverse transcriptases can help reduce the burden on developers by enabling short overall turnaround times, streamlining or eliminating purification, and simplifying shipping and storage. Selecting the appropriate components to address the challenges in your assay can be a daunting task. At Roche CustomBiotech, we are here to assist you in finding solutions and overcoming these obstacles. Explore our wide range of reagents designed for the unique requirements of centralized and point-of-care diagnostic assay development.

2:55 Refreshment Break in the Exhibit Hall with Poster Viewing
(Sponsorship Opportunity Available)

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences
Peter Foley, CEO and Founder, LetsGetChecked
In this fireside chat, Peter Foley, CEO and founder of LetsGetChecked, will explore the mission and vision that have driven the company's rapid growth and innovation in home health management. He will share insights into the journey of scaling from a direct-to-consumer model to a robust business-to-business platform, addressing the challenges of integrating health insights and advanced clinical diagnostics with exceptional customer care.

Plenary Keynote Fireside Chat: Talk Title to be Announced
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: Driving Innovation in Precision Medicine: CEO Perspective




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Susan Tousi, CEO, DELFI Diagnostics

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

WEDNESDAY, MARCH 12

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 PANEL DISCUSSION: Investing in Precision Medicine Innovation: What Defines Success?




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Ajit Singh, PhD, Partner, Artiman Ventures
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

9:00 Transition to Sessions

MARKET ACCESS FOR POCT AND HOME TESTING

9:05 Chairperson's Remarks

9:10 The Utility of Direct-Access Testing
Lesley Northrop, PhD, Chief Diagnostic Officer, Everly Health

Direct-access testing (DAT) allows individuals to order laboratory tests without a physician's order. This approach offers benefits such as increased patient autonomy, convenience, and earlier disease detection. This abstract explores the utility of DAT by examining its benefits and drawbacks, considering its impact on patient care, and discussing its role in the evolving healthcare landscape. Importantly review the regulatory landscape while highlighting the importance of patient safety and test accuracy.

9:40 Digital Health in Diagnostics and Point-of-Care
Maliheh Poorfarhani, Product and Service Partnering Tech Lead - Digital Solutions, Roche Diagnostics
Reflecting on how digital health can bring patient and data insight to the healthcare professionals for more accurate and timely decision making while patient stays at the comfort of their home. How we evaluate third parties or suppliers with the right digital health capabilities to bring this value to the market.

10:10 A New Point-of-Care Method for Concurrent Antibody & RNA Viral-Load Diagnostics
Tara Dalton, CEO, AltraTech Ltd

10:40 Coffee Break in the Exhibit Hall with Poster Viewing

DIRECT ACCESS TESTING

11:25 Chairperson's Remarks
Joe Keenan, Head, Life Sciences, LetsGetChecked

11:30 Precision Medicine Reimbursement—A Landscape Overview
Matt Bacigalupi, Director, Medicare Account Management, Novartis
Precision Medicine has rapidly evolved over the last decade; as a part of the dynamic future of healthcare, where do we stand with payer coverage and reimbursement? What steps can we take to better understand how coverage decisions are going to be made and what steps can be taken "pre" and "post" market entrance to help support coverage?

12:00 pm PANEL DISCUSSION: Direct Access Testing—Greatest Challenges in Getting Patients the Results They Need
Moderator: Joe Keenan, Head, Life Sciences, LetsGetChecked
Direct access testing or 'consumer-initiated testing' has grown exponentially in the last 5 years. Much is attributable to the familiarization of home testing kits such as those used during the pandemic for Covid-19 antigen testing. Patients are moving to managing their health on their own terms and we as an industry need to appropriately facilitate. This panel will discuss test access/ affordability as well as regulatory topics and operational aspects.
Panelists:
Robert Mordkin, MD, CMO, LetsGetChecked
Lesley Northrop, PhD, Chief Diagnostic Officer, Everly Health
Matt Bacigalupi, Director, Medicare Account Management, Novartis
Amy Summy, Executive Vice President and Chief Marketing Officer, Labcorp
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics

1:00 Lunch in the Exhibit Hall

2:00 Close of At-Home & Point-of-Care Diagnostics Conference

> "The TRICON is an industry-shaping event! Bringing together top researchers and business professionals to revolutionize global health!"
>
> *Research Associate, Sysmex Corp.*

TUESDAY, MARCH 11

7:00 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 Plenary Keynote Fireside Chat: A New Era in Healthcare: Making Precision Medicine a Reality
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Plenary Keynote Fireside Chat: Talk Title to be Announced
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine





Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Personalized or precision medicine depends upon linking prescribed therapies to diagnostics so that the right patient gets the right drug at the right time. Yet bringing the therapeutics and diagnostics together does not come easily as the pharmaceutical and diagnostic industries do not share the same business models or cultures. This panel discussion will explore what pharmaceutical executives look for when partnering with colleagues in diagnostics to develop targeted therapies.
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

9:30 Grand Opening Refreshment Break in the Exhibit Hall with Poster Viewing

MINIMAL RESIDUAL DISEASE: UTILITY IN PATIENT MANAGEMENT AND DRUG DEVELOPMENT

10:15 Chairperson's Remarks

10:20 Accelerating Drug Development in Prostate Cancer Using MRD as an Endpoint
Howard I. Scher, MD, Head of Biomarker Development Program, Member and Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center
High-risk prostate cancer has a high relapse and mortality rate, highlighting the need for more effective therapies. The ADAPPT protocol trial addresses this by enabling neoadjuvant treatment strategies to eradicate detectable disease in patients for whom single treatments are insufficient. Through a multiomic approach to MRD detection we aim to establish a six-month regulatory efficacy endpoint, which will help predict treatment resistance and expedite drug development to improve patient outcomes.

10:50 Harnessing Liquid Biopsies and AI for Precision Oncology
Justin Odegaard, MD, PhD, Vice President, Clinical Development, Guardant Health
Justin Odegaard, Vice President of Clinical Development at Guardant Health, will explore how liquid biopsy technology combined with AI is transforming precision oncology. The session will cover the latest breakthroughs in detecting minimal residual disease and applying genomic insights to optimize cancer treatment decisions, ultimately advancing patient outcomes in clinical care.

11:20 PANEL DISCUSSION: Challenges to Implementation of MRD in Clinical Development
Moderator: Christopher Conn, PhD, Director, Global Diagnostic Strategy, Precision Medicine, Amgen
Assessment of MRD (Measurable/Molecular Residual Disease) represents a powerful clinical tool for drug development. Evaluation of MRD is standard practice for drug development in many hematological malignancies and is increasing rapidly for many solid tumor indications and settings. Challenges associated with leveraging MRD in drug development and opportunities for MRD to reach its full potential in this regard will be discussed.
Panelists:
Fernando Cruz-Guilloty, PhD, Director, Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine
Justin Odegaard, MD, PhD, Vice President, Clinical Development, Guardant Health
Howard I. Scher, MD, Head of Biomarker Development Program, Member and Attending Physician, Department of Medicine, Memorial Sloan Kettering Cancer Center

11:50 Sponsored Presentation *(Opportunity Available)*

12:20 pm Session Break

12:25 Luncheon Presentation *(Sponsorship Opportunity Available)* **or Enjoy Lunch on Your Own**

12:55 **Session Break**

IMPLEMENTING PRECISION MEDICINE AND COMPANION DIAGNOSTICS (CONT.)

1:20 **Chairperson's Remarks**

1:25 **PANEL DISCUSSION: Best Practices for Development and Global Utilization of Precision Medicines**

Moderator: Hakan Sakul, PhD, Owner and President, Precision Dx Strategies, Inc.

While multiple cancer indications have been the primary beneficiaries of precision medicines, scientific and technological improvements are now enabling such medicines for non-cancer indications. This expert panel will focus on efforts to develop precision medicines, impact of technological advances on future medicines, advances in prevailing science across disease states, equitable access to precision medicine trials, current challenges in global regulatory and reimbursement environments, and ways to remove barriers to access.

Panelists:

Brian Caveney, MD, JD, MPH, CMO & CSO, President, Early Development Research Laboratories, Labcorp

Fernando Cruz-Guilloty, PhD, Director, Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine

Elaine Katrivanos, Vice President, Regulatory Affairs, Tempus

Jean-François Martini, PhD, MSc, Biomarker Clinical Assay and Technology Group Head, Translational Science Operations, Pfizer Oncology

Marielena Mata, PhD, Senior Director, Clinical Biomarkers, Vividion Therapeutics

2:25 **Sponsored Presentation** *(Opportunity Available)*

2:55 **Refreshment Break in the Exhibit Hall with Poster Viewing** *(Sponsorship Opportunity Available)*

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 **Chairperson's Remarks**
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 **Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences**
Peter Foley, CEO and Founder, LetsGetChecked
In this fireside chat, Peter Foley, CEO and founder of LetsGetChecked, will explore the mission and vision that have driven the company's rapid growth and innovation in home health management. He will share insights into the journey of scaling from a direct-to-consumer model to a robust business-to-business platform, addressing the challenges of integrating health insights and advanced clinical diagnostics with exceptional customer care.

Plenary Keynote Fireside Chat: Talk Title to be Announced
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: **Driving Innovation in Precision Medicine: CEO Perspective**




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Susan Tousi, CEO, DELFI Diagnostics

5:00 **Welcome Reception in the Exhibit Hall with Poster Viewing**

6:00 **Close of Day**

WEDNESDAY, MARCH 12

7:30 am **Registration and Morning Coffee**

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 **Chairperson's Remarks**
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 **Plenary Keynote Introduction (Sponsorship Available)**

8:15 PANEL DISCUSSION: **Investing in Precision Medicine Innovation: What Defines Success?**




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Ajit Singh, PhD, Partner, Artiman Ventures
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

9:00 **Transition to Sessions**

MARKET ACCESS FOR EARLY CANCER DETECTION AND LIQUID BIOPSY TESTING

9:05 **Chairperson's Remarks**

9:10 **U.S. Policy Considerations for Emerging Blood-Based Cancer Screening Technologies**
Nicholas Halzack, MPH, Director, Health Policy, Roche Diagnostics

As technology continues to advance towards new non-invasive cancer screening modalities, particularly blood-based testing, the U.S. health care system lags in its ability to ensure a pathway to coverage and access for patients. This talk will summarize the U.S. policy environment related to cancer screening coverage, identify gaps, and consider potential solutions to accommodate emerging blood-based cancer screening tests.

9:40 PANEL DISCUSSION: Improving Cancer Care Requires Payers at the Table

Moderator: Lauren Leiman, Executive Director, BLOODPAC Consortium

The engagement of payers is essential in ensuring patient access to liquid biopsy in cancer care. BLOODPAC aims to incorporate payer perspectives to inform standards and evidentiary frameworks, ensuring publications and frameworks align with payer values and needs to improve cancer patient access and outcomes.

Panelists:

Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

Robert Dumanois, Director, Reimbursement Strategy, Thermo Fisher Scientific

Amy McNeal, Director, Managed Care, Guardant Health

10:10 Sponsored Presentation *(Opportunity Available)*

10:40 Coffee Break in the Exhibit Hall with Poster Viewing

LIQUID BIOPSY BIOMARKERS IN CLINICAL TRIALS AND PATIENT MONITORING

11:25 Chairperson's Remarks

11:30 Leveraging ctDNA-Based Molecular Response Monitoring to Accelerate Clinical Development

Minakshi Guha, PhD, Associate Director, LBx Strategy, PSI, Oncology Precision & Translational Medicine, Takeda Pharmaceuticals

This presentation will cover: 1) how the integration of ctDNA as a molecular response biomarker in early clinical trials improves patient risk stratification; 2) investigating case studies that demonstrate how molecular response assessment using ctDNA can predict clinical outcomes; 3) harnessing ctDNA data alongside radiographic imaging for informed early Go/No-Go decisions in clinical trials.

12:00 pm Analytical Validation Continued, BLOODPAC's Generic MRD Protocol

Lauren Leiman, Executive Director, BLOODPAC Consortium

The BLOODPAC MRD AV working group has recently published the Tumor-informed MRD Generic Analytical Validation Protocols. As the field continues to expand, the group will work to develop tumor agnostic MRD AV protocols. The session will discuss how we got here, how we move forward, and how these decisions will impact the patient journey as well as work to reduce costs associated with treatment of disease recurrence.

12:30 Cancer Treatment Monitoring Using Cell-Free DNA Fragmentomics

Nicholas C. Dracopoli, PhD, CSO, DELFI Diagnostics

DELFI- tumor fraction (DELFI-TF) is a tumor agnostic, mutation independent whole genome sequencing test to determine the genome wide circulating tumor (ctDNA) burden. DELFI-TF scores are independent predictors of overall survival (HR = 9.84, 95% CI = 1.72-56.10, p < 0.0001). This presentation will discuss the potential to use cfDNA fragmentomes to estimate tumor burden in cfDNA for treatment response monitoring and clinical outcome prediction.

1:00 Lunch in the Exhibit Hall

2:00 Close of Liquid Biopsy Conference

TUESDAY, MARCH 11

7:00 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: THE PHARMACEUTICAL INDUSTRY AND PRECISION MEDICINE

8:00 Chairperson's Remarks
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 Plenary Keynote Fireside Chat: A New Era in Healthcare: Making Precision Medicine a Reality
Gabriele Allegri, MBA, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine

Plenary Keynote Fireside Chat: Talk Title to be Announced
Edward Abrahams, PhD, Former President, Personalized Medicine Coalition

8:45 PANEL DISCUSSION: The Pharmaceutical Industry and Precision Medicine





Moderator: Edward Abrahams, PhD, Former President, Personalized Medicine Coalition
Personalized or precision medicine depends upon linking prescribed therapies to diagnostics so that the right patient gets the right drug at the right time. Yet bringing the therapeutics and diagnostics together does not come easily as the pharmaceutical and diagnostic industries do not share the same business models or cultures. This panel discussion will explore what pharmaceutical executives look for when partnering with colleagues in diagnostics to develop targeted therapies.
Panelists:
Steffan Ho, MD, PhD, Vice President, Head of Translational Oncology, Pfizer
Andrea L. Stevens, PhD, Senior Director, Precision Medicine Access, J&J Innovative Medicine
Lourdes Barrera, PhD, Executive Director, Global Medical Affairs Oncology—Precision Medicine, Merck
Omar Perez, PhD, Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

9:30 Grand Opening Refreshment Break in the Exhibit Hall with Poster Viewing

SPATIAL PROFILING TO STUDY DISEASE BIOLOGY

10:15 Chairperson's Remarks
Chi-Ming Li, PhD, Senior Principal Scientist, Therapeutic Discovery, Amgen

10:20 Spatial Intelligence in Drug Discovery, Diagnosis, and Interventions: Use Cases in Cancer and Neurological Disorders
Stephen T. C. Wong, PhD, Chair & Professor, Houston Methodist Hospital and Weill Cornell Medical College
Recent advances in spatial biology, multiplex imaging, and artificial intelligence (AI) are transforming drug discovery, diagnosis, and therapeutic interventions. We developed a spatial intelligence pipeline that integrates these technologies with experimental biology to identify tumor heterogeneity, immune interactions, drug resistance, neuroinflammation, and therapeutic targets. We will highlight case studies in oncology, neurodegeneration, and stroke to demonstrate the growing importance of spatial intelligence in addressing key challenges in precision medicine.

10:50 Mapping Alveolar-Fibrotic Boundaries: Insights from High-Resolution Spatial Transcriptomics
Nicholas Banovich, PhD, Associate Professor and Director, Division of Bioinnovation and Genome Sciences, TGen
Pulmonary fibrosis (PF) is a chronic, progressive disease that represents the final stage of many interstitial lung diseases (ILDs). Using spatial transcriptomic technologies, we investigate the molecular dysregulation at boundaries between regions of advancing fibrosis and structurally normal alveoli. These results provide key insights into the pathobiology of PF.

11:20 Single-Cell and Spatial Multiomics Analysis Reveals Increased Chromatin Accessibility of Specific Transcription Factor Motifs in Activated Tregs
Chi-Ming Li, PhD, Senior Principal Scientist, Therapeutic Discovery, Amgen
Regulatory T (Treg) cells are primarily a subset of CD4+ T cells with well-known roles in immune homeostasis. We utilized single-cell RNA-sequencing to reveal Treg heterogeneity and denoted that signature genes of Treg cells in the activation states enriched with transcriptional or chromatin DNA binding factors, suggesting that chromatin remodeling or transcriptional regulation may play a role in activation. We further performed single-nucleus multi-omics analysis.

11:50 Sponsored Presentation *(Opportunity Available)*

12:20 pm Session Break

12:25 LUNCHEON PRESENTATION: From Biorepository to Breakthroughs: Accelerating Development with Spatial and Transcriptomic Analyses
DISCOVERY LIFE SCIENCES
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Therapeutic strategies targeting various cell types within the tumor microenvironment, including targeted tumor therapies, immune checkpoint inhibitors, and angiogenesis inhibitors, have underscored the need to understand the complexity of the tumor microenvironment at scale within specific oncological indications to inform new therapy efficacy. We have established a large, highly annotated biorepository, consisting of solid tissue samples in multiple matrices, to streamline and accelerate drug development. We have implemented multiple workflows focusing on AI-powered pathology and retrospective clinical biomarker testing to stratify biospecimens for cohort selection. These cohorts are further amendable to unbiased spatial and single cell transcriptomic analyses, generating a substantial data repository for current and future therapy development.

12:55 Session Break

SPATIAL BIOLOGY: MARKET PROJECTIONS AND FUTURE TRENDS

1:20 Chairperson's Remarks

1:25 Spatial Biology: Market Projections, Clinical Applications, and Future Trends
Rebecca Burnham, PhD, Senior Product Manager, DeciBio Consulting LLC
This presentation will explore the rapidly evolving field of spatial biology, focusing on its market dynamics, clinical applications, and future trends. Key points include analysis of market growth projections and regional trends; examination of spatial biology's impact on oncology research, neurodegenerative disease studies, and drug discovery; and discussion of future challenges, including the integration of AI and machine learning, standardization efforts, and ethical considerations in molecular profiling.

1:55 Using Spatial Biology and Single-Cell Analysis to Enable a Better Understanding of Biological Pathways
Bill Hyun, PhD, Venture Partner, Genoa Ventures
This presentation will cover how emerging technologies in spatial biology and single-cell analysis promise to enable better understanding of biological pathways, discovery of new biomarkers and drug targets, and more insightful translational research.

2:25 Moving beyond Histology: Bringing Spatialomics to the Clinic to Predict Cancer Progression in Barrett's Esophagus
Emmanuel Gorospe, M.D., MPH, FACG, FASGE, Gastroenterology Medical Director, Castle Biosciences
Advances in spatial biology are expanding our knowledge of diseases, enabling us to look deeper into tissue structures to identify molecular changes before they are diagnosed by standard histopathology. These advances are making personalized medicine possible and hold the promise of improving patient care. This talk will explore the development and use of a spatialomics-based test that is guiding management of patients with Barrett's esophagus by predicting the risk of progression to esophageal cancer.

2:40 Sponsored Presentation *(Opportunity Available)*

2:55 Refreshment Break in the Exhibit Hall with Poster Viewing *(Sponsorship Opportunity Available)*

PLENARY KEYNOTE SESSION: DRIVING INNOVATION IN PRECISION MEDICINE: CEO PERSPECTIVE

3:40 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

3:45 Plenary Keynote Fireside Chat: Patient-Centric Innovation—Redefining At-Home Health Experiences
Peter Foley, CEO and Founder, LetsGetChecked
In this fireside chat, Peter Foley, CEO and founder of LetsGetChecked, will explore the mission and vision that have driven the company's rapid growth and innovation in home health management. He will share insights into the journey of scaling from a direct-to-consumer model to a robust business-to-business platform, addressing the challenges of integrating health insights and advanced clinical diagnostics with exceptional customer care.

Plenary Keynote Fireside Chat: Talk Title to be Announced
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

4:15 PANEL DISCUSSION: Driving Innovation in Precision Medicine: CEO Perspective




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Lisa Alderson, CEO, Adela, Inc.
Alex Aravanis, MD, PhD, CEO, Moonwalk Biosciences
Susan Tousi, CEO, DELFI Diagnostics

5:00 Welcome Reception in the Exhibit Hall with Poster Viewing

6:00 Close of Day

WEDNESDAY, MARCH 12

7:30 am Registration and Morning Coffee

PLENARY KEYNOTE SESSION: INVESTING IN PRECISION MEDICINE INNOVATION

8:00 Chairperson's Remarks
Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter

8:05 Plenary Keynote Introduction (Sponsorship Available)

8:15 PANEL DISCUSSION: Investing in Precision Medicine Innovation: What Defines Success?




Moderator: Mara G. Aspinall, Partner, Illumina Ventures; Professor of Practice, Arizona State University; Editor, Sensitive & Specific: The Testing Newsletter
Panelists:
Ajit Singh, PhD, Partner, Artiman Ventures
Jenny Rooke, PhD, Managing Director, Genoa Ventures
Michael Hadjisavas, PhD, Executive Advisor, GreyBird Ventures LLC

9:00 Transition to Sessions

SINGLE-CELL SPATIAL BIOLOGY

9:05 Chairperson's Remarks

9:10 AI-Enabled Single-Cell Morphological Analysis in Multidimensional Real and Feature Space Using Image-Guided Cell Sorters

Yuhwa Lo, PhD, Professor, Electrical & Computer Engineering, University of California, San Diego

Using image-guided cell sorting systems supported by AI, we analyze morphological features and identify morphological biomarkers to relate cell morphologies to their genomic and proteomic characteristics and predict cell fate and detect cell histories, enabling the system to analyze the past, current, and future characteristics of cells. Hardware advances will also be discussed as they are key to generating high quality data for AI learning.

9:40 Mouse FFPE CODEX/Phenocycler Profiling Lends Insight into Nanoparticle Reprogramming of Melanoma

Joel C. Sunshine, MD, PhD, Assistant Professor, Dermatology, Pathology and Biomedical Engineering, Johns Hopkins School of Medicine

A major gap in spatial proteomics is the lack of verified mouse antibodies for application to mouse models of disease. Here, we present a novel CODEX/PhenoCycler panel of 28 validated antibodies for murine FFPE tissues. We will discuss our workflow and analysis pipeline and present data from studying the impact of reprogramming nanoparticle gene delivery nanoparticles on the murine melanoma TME.

10:10 Sponsored Presentation *(Opportunity Available)*

10:40 Coffee Break in the Exhibit Hall with Poster Viewing

SINGLE-CELL MULTIOMIC ANALYSIS

11:25 Chairperson's Remarks

11:30 Multimodal Single Cell Analyses Reveal Fibroblast Lineage Plasticity across Disease

Rachana Pradhan, PhD, Principal Scientist, gCS, Genentech

Fibroblasts play a crucial role in driving pathology across inflammatory and fibrotic diseases, as well as various solid cancer indications. Previously, we identified a Pi16 expressing fibroblast subset found across multiple tissues and diseases that functions as a reservoir, giving rise to activated fibroblasts. Using multimodal single cell datasets from preclinical models, we examine Pi16 fibroblasts' role in driving activated phenotypes, transcriptional regulators involved, and potential therapeutic opportunities.

12:00 pm Are More Genes Always Better? A Comparative Analysis of Xenium Prime vs. Targeted Gene Panels

Anna Elz, MSc, Research Manager, Innovation Lab, Immunotherapy Integrated Research Center, Fred Hutch Cancer Center

There are many choices and trade-offs when selecting an *in situ* spatial transcriptomic panel. We compare data from two platforms with small (400-500) and large (5,000-6,000) gene panels, including targeted genes, across multiple tissues to better understand how sensitivity, custom additions, and gene coverage influence detection under different biological scenarios.

12:30 Inferring Post-Transcriptional Regulation Using Single Cell Protein and mRNA Data from Human Testis

Saad Khan, Scientist, Laboratory of Nikolai Slavov, Northeastern University

We quantified the proteomes of 5,883 single cells from human testis using distinct mass spectrometry methods and developed BayesPG, a Bayesian model to systematically infer protein-mRNA discordances. BayesPG estimated consensus levels for 3,861 gene products, 28% of which exhibited significant discordances, contributing to ~1500 GO groups across 6 cell types. We observe that specialized, context specific functions, such as those related to spermatogenesis are regulated after transcription.

1:00 Lunch in the Exhibit Hall

2:00 Close of Spatial Biology and Single-Cell Multiomics Conference

> "The TRICON is the best meeting to keep up to date on a broad spectrum of topics from drug discovery and development to diagnostics."
>
> *Global Commercialization Marketing Manager, Promega*

WEDNESDAY, MARCH 12

1:30 pm Registration Open

ENGAGING WITH PAYORS ON EVOLVING REIMBURSEMENT POLICIES

2:00 Chairperson's Remarks
Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates, LLC

2:05 Medicare Update 2025: What You Need to Know That's New
Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates, LLC
The ultimate update on genomics at Medicare. We'll discuss what's new with maze of codes comprehensive genomic panel—and how the prices are being set. Next, we'll turn to the proliferation of MolDx "Z Codes," now tailored to specific different patients and situations. We'll discuss what's happening in all the MACs outside of MolDx—like NGS MAC and Novitas. Finally, we'll review how FDA approval is shaping coverage.

2:35 PANEL DISCUSSION: Payors and Labs in Transition
Moderator: Bruce Quinn, MD, PhD, Principal, Bruce Quinn Associates, LLC
Payors and specialty labs are adapting to evolving reimbursement policies, with new genomic technologies rapidly reaching the clinic. National experts will discuss both Medicare and commercial strategies, plus the impact of regulatory changes. Panelists will share practical insights for aligning lab operations with payor priorities and preparing for the challenges and opportunities ahead.
Panelists:
Ira Klein, MD, MBA, Vice President, Medical Affairs, Payer Relations, Tempus Labs, Inc.
Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
Gabriel Bien-Willner, MD, PhD, Medical Director, MolDx, Palmetto GBA
Stacey Brown, Market Access Lead, Optum Genomics
Clarisa Blattner, Senior Director, Revenue and Payor Optimization, XiFin, Inc.

3:35 Dessert Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:05 PANEL DISCUSSION: Tech Trends in Precision Medicine






Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine
Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.
Panelists:
Aaron Sin, Senior Director Research & Technology Development, Diagnostics & Regulated Materials, MilliporeSigma
Damon Hostin, Lead, Health System Market Access, Illumina, Inc.
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics
Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

4:45 Close of Day

THURSDAY, MARCH 13

8:00 am Registration and Morning Coffee

COVERAGE AND REIMBURSEMENT OF ADVANCED DIAGNOSTICS

8:30 Chairperson's Remarks

8:35 Current Trends in Utilization Management: What Labs Need to Know
Sarah Thibault-Sennett, PhD, Senior Director, Reimbursement Policy, American Clinical Lab Association
The US payer landscape is incredibly diverse with public and private payers, in addition to laboratory benefit managers that use constantly evolving prior authorization and other utilization management procedures. This session will explore current trends in utilization management procedures for laboratory services and highlight current advocacy activities to respond to these issues.

9:05 Billing Apocalypse: How Billing Practices Influence Clinical Laboratory Care, Patient Financial Toxicity, and Laboratory Success
Michael Astion, MD, PhD, Regional Medical Director & Professor, Laboratory Medicine and Pathology, Seattle Children's Hospital and the University of Washington
The clinical laboratory is a source of financial toxicity to patients. Here, we present common examples of financial toxicity in clinical lab services and discuss 7 achievable goals to help patients avoid financial toxicity and seek necessary care.

9:35 Diagnostics: Coding and Pricing Mistakes
Jim Almas, MD, Vice President and National Medical Director, Clinical Effectiveness, LabCorp
When planning for a market launch of a novel diagnostic in the US market, obstacles present themselves. Does my assay qualify for a Cat I code? Better to obtain a PLA code or an Administrative MAAA code? Downstream issues in these decisions? Will the coding pathway (involving the CAP-controlled groups like the Pathology Coding Caucus) matter? Crosswalk or gapfill?

10:05 Sponsored Presentation *(Opportunity Available)*

10:35 Networking Coffee Break

COVERAGE AND REIMBURSEMENT OF ADVANCED DIAGNOSTICS (CONT.)

10:55 Chairperson's Remarks

11:00 Looking across the Commercial Coverage Landscape
Gillian Hooker, PhD, CSO, Concert

During this session, we will discuss: 1) variation in coverage policies across the payer landscape and its root sources; 2) the challenges payers, labs, and providers face in determining whether a test will be covered; and 3) current and future solutions to bring clarity, consistency, and affordability to precision diagnostics.

11:30 Demystifying Medicare Coverage, the MolDX Program, and Z-Identifier Codes

Gabriel Bien-Willner, MD, PhD, Medical Director, MolDx, Palmetto GBA

This talk will focus on describing processes and procedures payors, including that Medicare must follow, how they make decisions, and how payor control tools created by MolDX can be used to make better and more reproducible coverage decisions.

12:00 pm New Policy Developments in Medicare Coverage for Novel Technology

Sandra Waugh Ruggles, PhD, Director, Policy Research, Stanford Byers Center for Biodesign; President, Summit Rock Strategy

The FDA authorizes hundreds of new medical devices and diagnostics annually, yet coverage, above nearly all other factors, has become the lynchpin for patient and physician access. Sandra will discuss research from the Stanford Mussallem Center for Biodesign Policy Program that sheds light on this landscape and opportunities for policy change.

12:30 Close of Conference

> "The TRICON is the most comprehensive conference in the field."
>
> *Professor, Public Health Research Institute*

Inaugural

Precision Medicine Beyond Oncology

NEW

Diagnostics and Personalized Medicine in Immunology, Neurology, and Metabolic Diseases

MARCH 12-13, 2025

WEDNESDAY, MARCH 12

1:30 pm Registration Open

PRECISION MEDICINE IN NEUROLOGY: DIAGNOSTICS, BIOMARKERS, AND DRUG DEVELOPMENT

2:00 Chairperson's Remarks

2:05 Personalized Precision Therapeutics: Intrathecal Antisense Oligonucleotide Therapy for Children with Autism and Epilepsy due to Nano-Rare Causal SCN2A Variants

Olivia Kim-McManus, MD, Associate Clinical Professor, Neurosciences, UCSD Rady Children's Institute for Genomic Medicine

SCN2A related disorder is a rare disease characterized by early onset intractable seizures, developmental delay, and gait ataxia with no approved treatments. The n-Lorem foundation is a non-profit organization which has created two individualized ASOs specifically targeted to each patient's SCN2A variant. We are currently in individual n=1 clinical trials with outcome measures tailored to each patient's phenotype.

2:35 The Emergence of High-Performance Blood Biomarkers to Transform Clinical Diagnosis in Alzheimer's Disease: Lessons from the PrecivityAD2 Blood Test

Joel Braunstein, MD, Co-Founder & CEO, C2N Diagnostics

The PrecivityAD2™ blood test is a breakthrough in Alzheimer's disease diagnosis, offering high concordance with amyloid PET scan and CSF biomarkers to identify brain amyloid pathology. This test leverages high-resolution mass spectrometry and multiple proteomic analysis to facilitate an early and accurate diagnosis for patients with cognitive impairment. The discussion will revolve around how the PrecivityAD2 test and other emerging molecular tools are redefining clinical care pathways in neurological medicine.

3:05 Antibody Discovery in Encephalitis and Multiple Sclerosis

Michael Wilson, MD, Professor, Neurology, University of California, San Francisco

There has been a surge in the recognition of many new central nervous system inflammatory disorders over the past 20 years. Oftentimes these diseases are defined by autoantibodies targeting specific neural antigens. Identifying these autoantibodies not only has accelerated the speed with which neurologists diagnose these conditions, but it has also deepened our understanding of the underlying immunology of these conditions and informed precision-based therapeutics that can be lifesaving.

3:35 Dessert Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:05 PANEL DISCUSSION: Tech Trends in Precision Medicine






Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine

Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.

Panelists:
Aaron Sin, Senior Director Research & Technology Development, Diagnostics & Regulated Materials, MilliporeSigma
Damon Hostin, Lead, Health System Market Access, Illumina, Inc.
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics
Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

4:45 Close of Day

THURSDAY, MARCH 13

8:00 am Registration and Morning Coffee

PRECISION MEDICINE IN OBESITY: PERSONALIZING GLP-1 THERAPIES

8:30 Chairperson's Remarks

8:35 AI Revolutionizing Precision Medicine: Unlocking GLP-1's Potential for Personalized Care

Elliott Green, CEO & Co-Founder, Dandelion Health

Precision medicine is opening new frontiers across multiple disciplines of medicine, but the opportunity to personalize patient care using GLP-1s may represent one of the greatest opportunities. However, unlocking these opportunities will take an AI revolution. Join Dandelion Health Co-founder and CEO Elliott Green as he explores how validated AI and real-world, unstructured data could pave the way for precision medicine with GLP-1 therapies.

9:05 The MyPhenome Test – A Commercial Precision Medicine Test for Obesity

Mark Bagnall, CEO, Phenomix Sciences

Obesity is a heterogeneous and multifactorial disease that affects over 1 billion people worldwide. Because of the heterogeneity of the disease, patients respond differently to anti-obesity interventions, including the new GLP-1 drugs. To better identify responders, Phenomix Sciences launched the MyPhenome test, a genetic test that identifies three phenotypes of the disease related to intervention response. The clinical demonstration of phenotypes and intervention response will be discussed at the session.

9:35 Precision Medicine Meets GLP-1: Personalized Care for Obesity and Diabetes

Avantika Waring, MD, CMO, 9amHealth

GLP-1 receptor agonists have emerged as highly effective treatments for obesity and diabetes, yet clinical response varies significantly. This presentation explores recent findings on predictors of GLP-1 efficacy, including genetic, metabolic, environmental, and behavioral indicators that correlate with successful weight loss and long-term maintenance, and glycemic control. This discussion will also evaluate several therapeutic options for obesity and diabetes using a precision medicine approach.

10:05 Sponsored Presentation *(Opportunity Available)*

10:35 Networking Coffee Break

PRECISION MEDICINE IN IMMUNOLOGY

10:55 Chairperson's Remarks

11:00 Precision Medicine for Immune-Mediated Diseases: Past Achievements and Future Prospects

Marc Levesque, PhD, Vice President, Immunology Discovery, Merck & Co.

Precision medicine approaches to autoimmune, autoinflammatory, and atopic diseases have been slow to impact patients; unmet need remains high in these diseases. The advent of targeted therapies and OMICs techniques has highlighted the need to target drugs to appropriate patient subsets. This presentation will examine past and current approaches to predicting drug responses and the use of genetic and diseased tissue OMICs to predict treatment responses to immune-mediated diseases.

11:30 AI-Driven Precision Medicine in Autoimmune Disorders

Luka Jelcic, Project Leader, DeciBio Consulting

This presentation will explore the transformative role of artificial intelligence in autoimmune disease management. Key points include AI applications in patient heterogeneity analysis, biomarker discovery, and early diagnosis; AI-driven personalized treatment strategies and drug discovery; and real-world case studies demonstrating the impact of AI on patient outcomes and healthcare costs in autoimmune disease management.

12:00 pm Prognostic and Predictive Biomarkers for Precision Medicine in IBD

Andres Hurtado-Lorenzo, PhD, Senior Vice President, Translational Research & IBD Ventures, Crohns & Colitis Foundation

This presentation showcases the integration of multiomics and machine learning for the discovery of prognostic and predictive biomarkers in Crohn's disease. Using state-of-the-art proteomics and transcriptomics, novel biomarkers were identified to identify, at disease diagnosis, patients at high risk of developing fibrotic and fistulizing complications, as well as predict response to anti-TNF therapy. These biomarkers have the potential to enable precision medicine for improved Crohn's disease management and patient outcomes.

12:30 Close of Conference

> "The Molecular Tri-Conference is one of our top conferences we sponsor, and certainly reaches our target customer base. The quality of leads that come from this conference are very high."
>
> *Director, Marketing Development, SeraCare*

WEDNESDAY, MARCH 12

1:30 pm Registration Open

HOME TESTING FOR INFECTIOUS DISEASES

2:00 Chairperson's Remarks

2:05 The Pros and Cons of Home Respiratory Testing

Norman Moore, PhD, Volwiler Senior Associate Research Fellow, Director, Infectious Diseases, Scientific Affairs, Abbott Laboratories

Home testing for COVID-19 was a major success for safely getting through the pandemic as people could safely return to work or social gatherings. That has opened the door to the demand for more at-home tests. This talk will go through pros and cons of home testing for infectious diseases so people can better understand the benefits and risks.

2:35 Breaking the Barriers for Remote Self-Swabbing to Detect Chlamydia, Gonorrhea, and HPV

Dina Greene, PhD, Clinical Professor, University of Washington

Access to appropriate testing is crucial for identification, appropriate management, and containment of sexually transmitted infections (STI), mitigating their impact on public health. Without access to diagnostics, people will often unknowingly spread infections throughout their community or miss valuable opportunities to ensure they are maintaining reproductive health. Combined, there is a need for accessible and comprehensive services to screen for Chlamydia, Gonorrhea, and HPV.

3:05 PANEL DISCUSSION: Comprehensive Stakeholder Engagement to Accelerate and Optimize Access: A Case Study of POC HCV Test

Moderator: Angela Stewart, Vice President, Global Government Affairs, Cepheid

A successful diagnostic test launch requires not only an "accurate test" with "strong clinical utility," but also requires both early and deep stakeholder engagement with regulators, payers, and other members of the healthcare ecosystem. We will discuss a successful case study that can be used as a model for stakeholder engagement across a wide variety of stakeholder groups including NIH, FDA, CDC, patient advocacy, professional societies, clinicians, and more.

Panelists:

David Pulliam, Director, Government Affairs, Gilead Sciences
Shivang Doshi, Director, Market Access Strategy, Cepheid
Meghan Spell, JD, MBA, Director, Growth and Strategy, Optum Genomics

3:35 Dessert Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:05 PANEL DISCUSSION: Tech Trends in Precision Medicine






Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine

Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.

Panelists:

Aaron Sin, Senior Director Research & Technology Development, Diagnostics & Regulated Materials, MilliporeSigma
Damon Hostin, Lead, Health System Market Access, Illumina, Inc.
Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences
Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics
Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

4:45 Close of Day

THURSDAY, MARCH 13

8:00 am Registration and Morning Coffee

CLINICAL METAGENOMIC SEQUENCING FOR DIAGNOSIS OF INFECTIONS

8:30 Chairperson's Remarks

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

8:35 Stewarding Next-Generation Sequencing Testing for Infectious Disease Diagnosis

Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children's Hospital Los Angeles; Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California

There is an increasing interest in the use of complex and expensive sequencing-based tests for the diagnosis of infectious diseases. Reports on the utility of the test have been variable. This presentation highlights challenges to the use of NGS tests and potential approaches to maximize the effectiveness of it.

9:05 Talk Title to be Announced

Erin H. Graf, PhD, D(ABMM), Associate Professor of Laboratory Medicine and Pathology; Co-Director, Microbiology Laboratory, Mayo Clinic Arizona

9:35 PANEL DISCUSSION: Clinical Metagenomic Sequencing: What's Next?

Moderator: Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

In this panel, discussants will review the current state of clinical metagenomic sequencing for diagnosis of infectious diseases, describe the clinical and public health impact of this novel technology, and consider ongoing challenges with regards to clinical indications, costs, and regulatory approval.

Panelists:

Jennifer Dien Bard, PhD, D(ABMM), Director, Microbiology and Virology, Children's Hospital Los Angeles; Professor, Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California
Steve Miller, MD, PhD, CMO, Delve Bio
Erin H. Graf, PhD, D(ABMM), Associate Professor of Laboratory Medicine and Pathology; Co-Director, Microbiology Laboratory, Mayo Clinic Arizona
Sivan Bercovici, PhD, CTO & Chief Business Officer, Karius, Inc.

10:05 Sponsored Presentation *(Opportunity Available)*

10:35 Networking Coffee Break

HOST RESPONSE PROFILING IN INFECTIOUS DISEASE

10:55 Chairperson's Remarks

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/ Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

11:00 Host Response Profiling and Artificial Intelligence-Machine Learning for Differential Diagnosis of Infections

Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/ Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

11:30 Host Response-Based Diagnostics for Presence, Type, Severity, and Treatment of Infectious Diseases

Purvesh Khatri, PhD, Professor, Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Stanford University

Infectious diseases remain a leading cause of death worldwide because despite technological advances, current diagnostic approaches are limited in detecting causative pathogen and fail to account for the host response to infection. Detrimental host responses can lead to increased morbidity and mortality. This talk will present recent technological advances that have enabled robust interrogation of the host response to infection and translation of these findings into rapid, point-of-care tests.

12:00 pm PANEL DISCUSSION: Host Response Profiling—A Test to Rule Them All?

Moderator: Charles Chiu, MD, PhD, Professor, Laboratory Medicine and Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory, UCSF School of Medicine

The panel will discuss state-of-the-art methods for evaluating host responses for diagnosis of infections, including RNA transcriptome sequencing, RNA gene profiling, proteomics, and serologic approaches, and the advantages versus disadvantages of each. The panel will also debate the potential of host response profiling for broad-based agnostic diagnosis of nearly all acute illnesses, whether infectious or non-infectious, as well as chronic syndromes such as long COVID and Lyme disease.

Panelists:

Jack Reifert, PhD, Senior Director, Development, Serimmune

Purvesh Khatri, PhD, Professor, Institute for Immunity, Transplantation and Infection, Center for Biomedical Informatics Research, Stanford University

Chris Woods, MD, MPH, CMO, Biomeme

12:30 Close of Conference

> "The TRICON allows me to participate in deep discussions about what is happening worldwide on circulating tumor cells. It was the most worthwhile event I participated in the last years, because of the level of discussions and the contacts I have made."
>
> *Researcher, Hospital AC Camargo Cancer Ctr*

WEDNESDAY, MARCH 12

1:30 pm Registration Open

EVIDENCE GENERATION FOR MULTI-CANCER EARLY DETECTION

2:00 Chairperson's Remarks

Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

2:05 One Year from the NHS Galleri Report Out: Will Half a Loaf Be Enough for Policy Decisions?

Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

A trial of a leading Multi-Cancer Early Detection (MCED) assay will report results on late-stage incidence in 2026, but not mortality data, the accepted gold standard for cancer screening tests. We suggest assembling relevant data to allow population implementation of these tests, including data from case-control data on test characteristics, real-world implementation studies, modeling studies, post market studies, and the collection of non-mortality endpoints of primary importance to patients.

2:35 NCI Update: Cancer Screening Research Network and Vanguard Study

Wendy Rubinstein, MD, PhD, Senior Scientific Officer, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health

Multicancer detection (MCD) tests have the potential to improve the reach and efficiency of cancer screening and to greatly expand the early detection opportunities for cancers without established screening, but the evidence base for their widespread use is limited. We will discuss anticipated early learnings from NCI's new Cancer Screening Research Network, created to evaluate emerging technologies for cancer screening, starting with MCDs in the Vanguard feasibility study.

3:05 PANEL DISCUSSION: What the MCED World Needs Now

Moderator: Larry Kessler, ScD, Professor, Health Systems and Population Health, University of Washington; Deputy Chair, MCED Consortium

While randomized controlled trials have been the standard for evaluating cancer screening technologies for several decades, there are challenges in bringing such studies to the fore regarding evaluation of multi-cancer early detection tests (MCEDs). This panel will review what studies need to be done in the short-to-moderate term, with what populations, with what endpoints, and what are the highest priority questions to ask of MCEDs now.

Panelists:

Wendy Rubinstein, MD, PhD, Senior Scientific Officer, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health

Robert A. Smith, PhD, Senior Vice President & Director, Center for Cancer Screening, American Cancer Society

Tomasz M. Beer, MD, CMO & Vice President, Multi-Cancer Early Detection, Exact Sciences

Megan P. Hall, PhD, Vice President, Medical Affairs, GRAIL

3:35 Dessert Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:05 PANEL DISCUSSION: Tech Trends in Precision Medicine

Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine

Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.

Panelists:

Aaron Sin, Senior Director Research & Technology Development, Diagnostics & Regulated Materials, MilliporeSigma

Damon Hostin, Lead, Health System Market Access, Illumina, Inc.

Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences

Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics

Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

4:45 Close of Day

THURSDAY, MARCH 13

8:00 am Registration and Morning Coffee

CLINICAL ADOPTION OF CANCER SCREENING AND MULTI-CANCER EARLY DETECTION

8:30 Chairperson's Remarks

8:35 Talk Title to be Announced

Robert A. Smith, PhD, Senior Vice President & Director, Center for Cancer Screening, American Cancer Society

9:05 Perspectives on Clinical Adoption Barriers to Blood-Based Multi-Cancer Early Detection Tests across Stakeholders

Arushi Agarwal, Partner, Health Advances LLC

Our team conducted a survey amongst healthcare providers (HCPs), payers, and patients within the U.S. health system to understand the current utilization of cancer screening tests and the anticipated barriers to widespread adoption of blood-based MCED tests. The results indicated significant enthusiasm for MCED adoption, but also highlighted a number of barriers that still exist before the value proposition of MCEDs can be truly realized.

9:35 Policy Barriers to Widespread Adoption of Blood-Based Cancer Screening

Emma Alme, PhD, Senior Director, Public Policy, Guardant Health

Even once they have FDA approval, blood-based screening tests face multiple policy barriers that can impact their adoption as a cancer screening tool. This session will discuss the regulatory and reimbursement challenges that influence patient access to and provider adoption of innovative screening tests and explore potential solutions.

10:05 Sponsored Presentation *(Opportunity Available)*

10:35 Networking Coffee Break

CANCER SCREENING AND EARLY DETECTION

10:55 Chairperson's Remarks

11:00 Biomarker Trajectories for Cancer Screening and Early Detection

Sam Hanash, MD, PhD, Director, Red & Charline McCombs Institute; Evelyn & Sol Rubenstein Distinguished Chair, Cancer Prevention; Professor, Clinical Cancer Prevention-Research, Translational Molecular Pathology, University of Texas MD Anderson Cancer Center

Detecting cancer at an early stage requires regular screening. Establishing trajectories of biomarkers over time as part of multi-cancer early detection blood tests improves performance compared to a single threshold tests. Evidence to this effect will be presented.

11:30 The Evolution of Biomarkers in Cancer Detection and Screening: Past, Present, and Future

Sudhir Srivastava, PhD, Chief, Cancer Biomarkers Research Group, NIH NCI

Screening is improved for cancers with an established early asymptomatic phase and available clinically validated, safe, sensitive, specific, and straightforward screening test with strong patient adherence, acceptance by patients and clinicians, and cost effectiveness. Biomarkers, including multi-cancer early detection tests, could play significant roles in screening and early detection. We will discuss the evolution of biomarker-based tests over the years and lessons learned from their applications to improve early detection.

12:00 pm Predicting the Outcome of the NHS Galleri Trial

Ruth Etzioni, PhD, Professor, Public Health Sciences, Fred Hutch Cancer Center

The NHS Galleri trial is an unprecedented cancer screening trial in the UK. It will evaluate the effect of the Galleri test on the incidence of late-stage disease among the targeted cancers over a follow-up interval of only 3 years. We predict the outcome of the Galleri trial using a model of cancer natural history that projects late-stage reduction using a test with a specified sensitivity for each targeted cancer.

12:30 Close of Conference

> "This is a great conference for bringing together industry, clinical providers, and academic researchers. It has a good balance of current medical practice and forward looking research."
>
> *Principal Member of Technical Staff, Sandia National Laboratories*

WEDNESDAY, MARCH 12

1:30 pm Registration Open

REGULATORY IMPACT ON BIOMARKERS AND COMPANION DIAGNOSTICS DEVELOPMENT

2:00 Chairperson's Remarks

2:05 FDA LDT Rulemaking: Impact on Patient Testing and Lessons Learned

Jai Pandey, PhD, Head, Global Device Regulatory IVD/CDx and Digital Health, Sanofi

This session explores the FDA's recent rulemaking efforts surrounding Laboratory Developed Tests (LDTs) and their impact on patient testing. It highlights the regulatory shifts aimed at ensuring the safety, effectiveness, and reliability of LDTs, while addressing challenges faced by laboratories in complying with new standards. Key lessons learned from this regulatory evolution are discussed, including implications for patient care, diagnostic innovation, and the balance between clinical flexibility and regulatory oversight.

2:35 The Future of Precision Medicine under New LDT Regulation

David Cavanaugh, Founding Partner, DeciBio Consulting LLC

This presentation will discuss how the new regulations might affect the development and adoption of personalized diagnostic tests. Key points include balancing innovation with regulatory compliance; potential effects on patient access to novel tests; and impact on rare disease testing and oncology diagnostics.

3:05 PANEL DISCUSSION: Navigating Regulatory Barriers for LDTs: Ensuring Access and Innovation in Clinical Trials

Moderator: Jai Pandey, PhD, Head, Global Device Regulatory IVD/CDx and Digital Health, Sanofi

Regulatory oversight for Laboratory Developed Tests (LDTs), such as FDA LDT rulemaking and EU IVDR, may limit test availability, impacting clinical trial efficiency and post-trial adoption. Stricter regulations could delay access to critical diagnostics, affecting patient selection and trial outcomes. Post-trial, regulatory hurdles could hinder the integration of companion diagnostics, slowing advances in personalized treatment. Balancing oversight with accessibility is essential to support innovation and ensure effective patient care.

Panelists:

Christopher Conn, PhD, Director, Global Diagnostic Strategy, Precision Medicine, Amgen

David Cavanaugh, Founding Partner, DeciBio Consulting LLC

Lakshman Ramamurthy, PhD, Vice President, Regulatory Affairs, GRAIL

Alberto Gutierrez, PhD, Partner, NDA Partners LLC

3:35 Dessert Break in the Exhibit Hall with Poster Viewing

PLENARY KEYNOTE SESSION: TECH TRENDS IN PRECISION MEDICINE

4:05 PANEL DISCUSSION: Tech Trends in Precision Medicine

Moderator: Jonathan D. Grinstein, PhD, North America Editor, Inside Precision Medicine

Leading technology companies will discuss future trends, needs, and solutions needed to drive precision medicine forward, including innovation in genomics and diagnostics, artificial intelligence and digital tech, multiomic analysis, biomarkers, and clinical trials.

Panelists:

Aaron Sin, Senior Director Research & Technology Development, Diagnostics & Regulated Materials, MilliporeSigma

Damon Hostin, Lead, Health System Market Access, Illumina, Inc.

Shawn Fahl, VP Lab Operations, Cell Services & R&D, Biospecimens, Discovery Life Sciences

Shawn Carlson, Vice President, Head of Market Access, Roche Diagnostics

Suzanne Belinson, PhD, Vice President, Commercial Markets, Tempus, Inc.

4:45 Close of Day

THURSDAY, MARCH 13

8:00 am Registration and Morning Coffee

ADVANCING PRECISION MEDICINE THROUGH BIOMARKER LEGISLATION

8:30 Chairperson's Remarks

8:35 Value of Biomarker Testing by Stakeholders: Patient, Provider, and Payer Perspectives Shaping the Market

Julie Wiedower, Senior Director, Medical Affairs, Managed Care, Guardant Health

Biomarker testing is guideline-recommended, but many systemic barriers lead to underutilization of testing and targeted therapies that benefit patients. The way that biomarker testing is evaluated differs by stakeholders in ways that overlap and diverge. In this session, we explore the outcomes of biomarker testing by stakeholders and identify opportunities for evidence generation and framework expansion to enhance access to guideline-recommended care.

9:05 The Landscape and Impact of State Biomarker Testing Laws: Opportunities and Challenges for Clinical Laboratories

Paul Sheives, MS, JD, Vice President, Government Affairs, Myriad Genetics

In recent years, state legislators have introduced dozens of measures requiring health insurers to cover a diverse array of biomarker tests. This surge in legislative activity reflects policymakers' commitment to enhancing

access to biomarker testing. However, it also signifies a significant shift in market dynamics, presenting implementation challenges for affected stakeholders. Join us as we explore the evolving landscape of coverage and patient access within this dynamic field of medicine.

9:35 PANEL DISCUSSION: Practical Considerations in Leveraging Biomarker Bills and Similar Initiatives to Drive Access for Your Test

Moderator: Damon Hostin, Lead, Health System Market Access, Illumina, Inc.

While the American Cancer Society/Cancer Action Network has been very successful in shepherding 20 bills requiring commercial insurers and state Medicaid programs to cover biomarker testing, the bills have not resulted in broader coverage for many lab tests. We'll explore the underlying payer objections to changing policies, why payers think their policies are compliant, and what you can do to leverage mandates to gain positive coverage for your biomarker test.

Panelists:

John L. Fox, MD, Senior Medical Director for the Americas, Illumina, Inc.

Hilary Gee Goeckner, MSW, Director, State and Local Campaigns, Access to Care, American Cancer Society Cancer Action Network (ACS CAN)

10:05 Sponsored Presentation *(Opportunity Available)*

10:35 Networking Coffee Break

ADVANCING PRECISION MEDICINE THROUGH BIOMARKER LEGISLATION (CONT.)

10:55 Chairperson's Remarks

Burns Blaxall, PhD, Senior Vice President, Precision Medicine, Aranscia; Adjunct Professor, University of Cincinnati

11:00 Advancing Precision Medicine through Biomarker Legislation

Burns Blaxall, PhD, Senior Vice President, Precision Medicine, Aranscia; Adjunct Professor, University of Cincinnati

In general, healthcare in the United States tends to be reactive. Precision Medicine, including germline and somatic testing as well as pharmacogenomics, aims to shift healthcare from reactive to proactive. Among the key challenges to implementing precision medicine is payor coverage for testing and services. Recent and pending legislation aims to address these challenges. This presentation will address the key challenges and legislative efforts to enhance implementation of precision medicine.

11:30 Biomarker Legislation to Catalyze Adoption of Precision Medicine

Kristine Ashcraft, MBA, Founder & President, YouScript

The ACS Cancer Action network launched a biomarker testing campaign to align commercial and Medicaid insurance coverage for somatic and germline genetic testing, including PGx, with the evolving evidence. Meanwhile, federal efforts such as the Right Drug Dose Now Act are aiming to address other barriers to realizing the promise of precision medicine in improving patient care. Learn about these legislative efforts and how they can impact patient care delivery.

12:00 pm PANEL DISCUSSION: Leveraging Biomarker Legislation toward Equitable Access to Precision Medicine

Moderator: Burns Blaxall, PhD, Senior Vice President, Precision Medicine, Aranscia; Adjunct Professor, University of Cincinnati

Precision Medicine is a proactive shift in healthcare. It largely focuses on genetic testing, whether germline, somatic, or pharmacogenomics, to inform proactive disease risk evaluation and to guide treatment decisions. Despite many advances in precision medicine, payor coverage for testing and services remains limited. This panel will explore recent and pending legislative efforts to enhance coverage for, and utilization of, precision medicine and proactive care.

Panelists:

Kristine Ashcraft, MBA, Founder & President, YouScript

12:30 Close of Conference

> "The Tri-Conference captured the key topics of the moment combined with a very diverse set of attendees."
>
> *CCO, OmniSeq*

32nd International

Precision Med TRI-CON

March 11-13, 2025 | Town and Country Resort San Diego, CA

PRESENT A POSTER and SAVE $50!

Cambridge Healthtech Institute encourages attendees to gain further exposure by presenting their work in the poster sessions. To secure an onsite poster board and/or ensure your poster is included in the conference materials, your full submission must be received, and your registration paid in full by January 24, 2025.

Register and indicate that you would like to present a poster. Once your registration has been fully processed, we will send an email with a unique link and instructions for submitting your abstract and other materials. Please see website for more information.

Reasons you should present your research poster at this conference:

- Your research will be seen by our international delegation, representing leaders from top pharmaceutical, biotech, academic and government institutions
- Discuss your research and collaborate with other attendees
- Your poster presentation will be published in our conference materials
- Receive $50 off your registration

MEDIA PARTNERS

Official Publication

Diagnostics World

Lead Sponsoring Publications

AI in Precision Oncology · Bio-IT World · Clinical Research News (Clinical Trials to the Clinic) · GEN Genetic Engineering & Biotechnology News · Inside Precision Medicine

Sponsoring Publications

American Pharmaceutical Review · DDN Exploring Drug Discovery and Development · Pharmaceutical Outsourcing · The Scientist Exploring Life, Inspiring Innovation

Sponsoring Associations

Biocompare The Buyer's Guide for Life Scientists · labcompare · PMC Personalized Medicine Coalition

Web Partner

BIG4BIO

Join Us in San Diego

HOTEL & TRAVEL INFORMATION

Conference Venue and Hotel:
Town and Country Resort
500 Hotel Circle North
San Diego, CA 92108

T: 800-772-8527

Discounted Room Rate: $249 s/d
Discounted Room Rate Cut-off Date: February 12, 2025

For hotel reservations, please go to the Travel Page of TriConference.com



Can't Make it to San Diego?

Connect from anywhere.
Join via our robust virtual platform and access these dynamic features.

- INTUITIVE INTERFACE
- PANEL DISCUSSIONS
- LIVE CHAT
- RECORDED SESSIONS
- COMPANY BRANDING
- DOWNLOADS
- LIVE SESSIONS
- POSTER SESSIONS